High-Dose Intravitreal Topotecan for Retinoblastoma With Subretinal Seeds: A Well-Tolerated and Efficacious Approach. J Pediatr Hematol Oncol 2026 Jul 01;48(5):242-245
Date
06/09/2026Pubmed ID
42263182DOI
10.1097/MPH.0000000000003221Scopus ID
2-s2.0-105043501104 (requires institutional sign-in at Scopus site)Abstract
BACKGROUND: High-dose intravitreal topotecan (90 μg) has emerged as a promising treatment option for refractory or recurrent retinoblastoma with active tumor and subretinal seeds, offering localized disease control while minimizing systemic toxicity.
OBSERVATIONS: In this 5-patient case series, tumor regression was achieved in 4 cases without significant adverse effects. One patient required enucleation due to disease progression. Timely administration and consistent follow-up were identified as key factors influencing treatment outcomes.
CONCLUSIONS: High-dose intravitreal topotecan demonstrates meaningful therapeutic potential in achieving localized tumor control with an acceptable safety profile, supporting further investigation into its role in managing refractory retinoblastoma.
Author List
Palia R, Alvarado W, Becktell K, Ramasubramanian A, Liberio NAuthors
Kerri Becktell MD Associate Professor in the Pediatrics department at Medical College of WisconsinAparna Ramasubramanian MBBS Chief, Professor in the Ophthalmology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
HumansIntravitreal Injections
Retinal Neoplasms
Retinoblastoma
Topoisomerase I Inhibitors
Topotecan









